It’s been a little over 20 years since the first human genome was sequenced. Genome sequencing is technology that reveals the genetic blueprint of a living organism.
The original cost of sequencing the human genome of one individual was one billion dollars. That’s right…a billion.
However, due to the brilliant work of Jay Flatley, the founder of a company called Illumina (NASDAQ: ILMN), the cost today is under $1000…and falling rapidly.
Why is this so significant?
It’s significant because our society is moving in the direction of disease prevention and not just treatment.
The government has realized what insurance companies have known for awhile: that it is cheaper to prevent illness than to treat it.
This is where genome sequencing comes in.
Imagine going to the doctor and having your genome sequenced at no cost to you. The results come back and show that you are predisposed to various diseases.
This information would enable you to take control over your personal health like never before!
The genomics revolution is in its very early stages…and I believe it will explode over the next 25 years.
Here’s a list of several companies that are set up to benefit from that explosion:
Illumina (NASDAQ: ILMN) – Right now, Illumina is the leading company in genomics, and will be for the foreseeable future. They make the machines that make genome sequencing possible. They have a market value of $44.39 billion, so they are not a small company…but they still have plenty of room to grow.
Pacific Biosciences of California (NASDAQ: PACB) – Like Illumina, this company sells gene-sequencing machines. They are not competing with Illumina, because their machines are designed to read longer strings of DNA. They are a much smaller company, with a market cap of only $485 million.
Invitae Corporation (NYSE: NVTA) – Invitae is taking advantage of the declining cost of gene sequencing, and bringing it to the masses. Their goal is to enable people to have their genome sequenced when they visit the doctor. Invitae only has a market cap of $558 million, so they are a very small company as well.
Keep all three of these stocks on your radar. I would consider any one of these if you’re interested in investing in the genomics revolution!